Author Archive: Daniel Seaton

Daniel Seaton

Daniel Seaton is BIO's Director for Health Communications, where he handles communications on public policy issues affecting members of BIO's health and emerging company sections. Prior to joining BIO in August 2013, he spent four years in communications at the Pharmaceutical Research and Manufacturers of America. The best part of his job is educating audiences about the many benefits the bioscience industry produces for patients, consumers, and the economy as a whole. Daniel enjoys hiking, camping, and, when he can find a game, playing bridge. Having grown up in New Mexico, one of his favorite foods is roasted green chile. He has a Master's degree in Public Relations and Corporate Communications from Georgetown University.

Latest Posts

Report: Low Compliance with ACA Charity Care Requirements among 340B Hospitals

Earlier this week, the Alliance for Integrity and Reform of 340B, of which BIO is a member, released a new report examining hospitals’ compliance with the charity care requirements of the Affordable Care Act (ACA). The report found that large numbers of both 340B and non-340B hospitals are not complying with protections contained in the ACA for low-income patients, such as rules designed to ensure they are made aware of a hospital’s charity care program Read More >

Health  |  Leave a comment  |  Email This Post
Tags: ,

Points to Consider about the Center for American Progress Prescription Drug Discussion

health care, medicine

This afternoon, the Center for American Progress (CAP) Action Fund hosted an obviously one-sided discussion on prescription drug pricing. Below are some key questions and points to consider in this important debate that you likely didn’t hear about at the CAP event: Prescription Drugs Only Small Part of Overall Health Spending: Despite the increasingly shrill rhetoric on this issue, the fact remains that prescription drugs are only a small fraction of total health expenditures in Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , ,

Facing growing pressure, N.Y. insurers agree to lift restrictions on hepatitis c therapies

Wall Street Journal

Last week, we wrote about the mounting evidence of insurer discrimination and coverage denials for patients with certain high-cost health conditions such as HIV and hepatitis C. In many cases, insurers have been denying new hepatitis C treatments to patients unless their livers showed signs of severe damage – despite guidelines from major medical societies recommending the drugs for nearly all hepatitis C patients. Today, the Wall Street Journal reported some good news for hepatitis Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , ,

ICYMI: One Patient’s Perspective: Having Cancer Doesn’t Make Me Worth Less

Yesterday, cancer survivor and health economist Jennifer Hinkel shared her perspective on the Institute for Clinical and Economic Review’s Value Assessment Framework: An organization named ICER — the Institute for Clinical and Economic Review — is making big waves in health care circles. It calls itself “a trusted non-profit” despite suggestions that it takes significant funding from the health insurance industry. ICER has just released a draft report about treatment for a rare and difficult-to-treat cancer called Multiple Myeloma. Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , ,

Patient and provider groups ask CMS: Don’t turn back the clock on rheumatic disease care

synthetic biology

Writing today in The Hill, Ann Palmer of the Arthritis Foundation and Joan Von Feldt of the American College of Rheumatology have a message for CMS: don’t turn back the clock on rheumatic disease care by proceeding with the recently proposed payment cuts in the Medicare Part B program. They write: The Centers for Medicare & Medicaid Services (CMS) recently proposed additional Medicare Part B payment cuts that would make it exceedingly more difficult for Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , ,